Pre-earnings brief
Reports
Thu, Feb 6, 2020
Est. EPS
—
Est. revenue
—
Implied move
±14.9%
EPS beat rate
25%
Smith & Nephew plc (SNN) is a global medical technology company that specializes in advanced wound management, surgical devices, and orthopedic reconstruction. Operating in the health care sector, the company plays a crucial role in improving patient outcomes and enhancing the quality of care across various medical fields.
Last quarter
In the last quarter, Smith & Nephew reported an EPS of $0.92, which was in line with expectations. The stock saw a modest increase of 1.23% the following day, indicating a generally positive market reception.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
+19.92%
Avg 1-day reaction
+0.05%
Overall, expectations for Smith & Nephew's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see if the company can maintain its revenue growth amid competitive pressures.
Bull case
The optimistic view hinges on strong demand for innovative medical devices and successful market penetration, which could lead to better-than-expected revenue and EPS.
Bear case
Conversely, challenges such as supply chain disruptions or increased competition could negatively impact sales and margins, leading to disappointing results.
The print will turn on these.
Q1
What will be the revenue growth rate for the surgical devices segment?
This segment is crucial for the company's overall performance, and any significant deviation from expectations could impact investor confidence.
Q2
How will management address supply chain challenges affecting production?
Supply chain issues have been a concern for many companies; how Smith & Nephew navigates these challenges will be critical for maintaining growth.
Why consensus could be wrong
The Street may be underestimating the potential for strong demand in the advanced wound management segment, which could drive unexpected revenue growth.
Supporting evidence
Historical data shows that Smith & Nephew has consistently performed well in this segment, even amid broader market challenges.
Options pricing suggests a significant move, indicating that traders expect more volatility than the consensus forecasts.
The company's recent product launches could lead to increased market share, which analysts may not fully account for.
Key risk
If the surgical devices segment shows stronger growth than anticipated, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating the sustainability of Smith & Nephew's growth amid competitive pressures and potential supply chain disruptions.
Bull confirmed if
A revenue growth rate of over 10% in the surgical devices segment would confirm the bull case.
Bear confirmed if
If revenue growth falls below 5%, it would confirm the bear case.
What the market is pricing for the move.
Implied Move
±14.88%
Historical Avg
±2.4%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±14.9% while SNN has averaged ±2.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
19.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Smith & Nephew beats expectations, history suggests the stock could rise by about 1% to 2% on the first day, confirming positive market sentiment.
In line / cautious
If results are in line but management expresses caution, the stock may see a muted reaction, potentially leading to a slight decline.
Miss
A miss on earnings could lead to a drop of around 1% to 2% based on historical patterns, reflecting disappointment among investors.
The lines on the call that would change the story.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—